Inhibition of BET Recruitment to Chromatin As An Effective Treatment for MLL-Fusion Leukaemia
Mark A. Dawson(The University of Melbourne), Brian J.P. Huntly(Wellcome/MRC Cambridge Stem Cell Institute), Alan K. Burnett(Cardiff University), George Giotopoulos(Wellcome/MRC Cambridge Stem Cell Institute), Rab K. Prinjha(GlaxoSmithKline (United Kingdom)), Wai-In Chan(University of Cambridge), Dave Lugo(GlaxoSmithKline (United Kingdom)), Samuel C. Robson(University of Portsmouth), Philip D. Jeffrey(Princeton University), Konstanze Döhner(University Hospital Ulm), Antje Dittman, Chun‐wa Chung(GlaxoSmithKline (United Kingdom)), Olivier Mirguet(GlaxoSmithKline (France)), Carsten Hopf(Technische Hochschule Mannheim), Marcus Bantscheff(Roche (Switzerland)), Tony Kouzarides(The Gurdon Institute), Ruud Delwel(Erasmus MC Cancer Institute), Emma Gudgin(University of Cambridge), Sören Beinke(GlaxoSmithKline (United Kingdom)), Gerard Drewes(Unknown), Peter E. Soden(GlaxoSmithKline (United Kingdom)), Kevin Lee(GlaxoSmithKline (United Kingdom)), Mikhail M. Savitski(European Molecular Biology Laboratory), Kurt R. Auger(Research Triangle Park Foundation), Carola Huthmacher
Cited by 38
Related Papers
Regulation of chromatin by histone modifications
|Cell Research|2011|5.9k
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k